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Objective. To evaluate the impact of comorbidities on physical function in patients with ankylosing spondylitis 
(AS) and psoriatic arthritis (PsA).
Methods. This was a cross- sectional analysis of the baseline visit from the Cardiovascular in Rheumatology study. 
Multivariate models with physical function as the dependent variable (Bath Ankylosing Spondylitis Functional Index 
and Health Assessment Questionnaire for AS and PsA, respectively) were performed. Independent variables were a 
proxy for the Charlson Comorbidity Index (CCIp; range 0–27), sociodemographic data, disease activity (erythrocyte 
sedimentation rate [ESR] and Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] in AS; Disease Activity 
Score in 28 joints [DAS28] using the ESR in PsA), disease duration, radiographic damage, and treatments. Results 
were reported as beta coefficients, 95% confidence intervals (95% CIs), and P values.
Results. We included 738 patients with AS and 721 with PsA; 21% of patients had >1 comorbidity. Comorbidity 
burden (CCIp) was independently associated with worse adjusted physical function in patients with PsA (β = 0.11). 
Also, female sex (β = 0.14), disease duration (β = 0.01), disease activity (DAS28- ESR; β = 0.19), and the use of 
nonsteroidal antiinflammatory drugs (β = 0.09), glucocorticoids (β = 0.11), and biologics (β = 0.15) were associated 
with worse function in patients with PsA. A higher education level was associated with less disability (β = –0.14). In 
patients with AS, age (β = 0.03), disease activity (BASDAI; β = 0.81), radiographic damage (β = 0.61), and the use of 
biologics (β = 0.51) were independently associated with worse function on multivariate analyses, but CCIp was not.
Conclusion. The presence of comorbidities in patients with PsA is independently associated with worse physical 
function. The detection and control of the comorbidities may yield an integral management of the disease.
INTRODUCTION
Physical function is a crucial consideration in patients 
with spondyloarthritis (SpA) and, along with health- related 
quality of life, is considered a major outcome in patients with 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Fur-
thermore, functional improvement is one of the ultimate goals 
of therapy for patients with AS and PsA. Patients with AS have 
increased comorbidity when compared to the general popula-
tion, particularly with regard to some specific disorders, such as 
cardiovascular disease (CVD) and osteoporosis (1). Patients with 
PsA also have increased comorbidities, such as CVD, diabe-
tes mellitus, metabolic syndrome, and depression, and more than 
50% have >1 comorbidity (2).
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Although both conditions have an impact on physical func-
tion, which is directly related to disease activity and structural 
damage (3,4), other factors may also deteriorate physical func-
tion in patients with chronic inflammatory rheumatic diseases. For 
example, comorbidity has been found to be relevant in patients 
with rheumatoid arthritis (RA), where functional status becomes 
worse with increasing levels of comorbidity, independently of 
disease activity (5). However, fewer studies have focused on the 
impact of comorbidity on physical function in patients with AS and 
PsA, even though the physical function impairment and the quality 
of life limitations of such patients are similar to those with RA (6). 
Taking together all these considerations, the main purpose of the 
current study was to analyze the impact of comorbidities on phys-
ical function in Spanish patients with AS and PsA.
PATIENTS AND METHODS
Study design. This was a cross- sectional study draw-
ing on baseline data from the Cardiovascular in Rheumatology 
(CARMA) project, an ongoing multicenter 10- year prospective 
national study of a cohort of patients with chronic inflammatory 
rheumatic diseases. It included patients with RA, AS, and PsA, 
along with age- and sex- matched subjects without chronic inflam-
matory rheumatic diseases from 67 randomly selected Spanish 
outpatient rheumatology clinics (recruited from July 2010 to 
 January 2012). The patients’ recruitment criteria have previously 
been published (7).
Patients. For this study, 738 patients with AS (modified New 
York criteria) and 721 with PsA (Moll and Wright criteria) were ana-
lyzed. The study was performed following the principles outlined 
in the Helsinki Declaration, and written informed consent was 
obtained from all subjects before their inclusion in the CARMA pro-
ject. The study protocol was approved by the Ethics Committee 
for Clinical Research of Lugo, Galicia, Spain (protocol #2009/077).
Variables and operative definitions. Dependent 
variable. The main outcome was physical function, measured 
through the Spanish validated versions of the Bath Ankylosing 
Spondylitis Functional Index (BASFI) in patients with AS, and the 
Health Assessment Questionnaire (HAQ) in patients with PsA.
Independent variables. The independent variables includ-
ed: 1) demographic data: age, sex, and education level; 2) 
disease activity: assessed in patients with AS by persistently 
raised erythrocyte sedimentation rate (ESR) or C- reactive pro-
tein and by the Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI), Spanish validated version; in patients with 
PsA, the Disease Activity Score in 28 joints (DAS28) using 
the ESR was used; 3) disease duration; 4) radiographic dam-
age, defined in this study as “spinal radiographic changes” 
for AS and “presence of erosions” for patients with PsA, ob-
served in standard radiographs; 5) treatments for the rheu-
matic disease and comorbidities; 6) comorbidities recorded 
as dichotomous variables and also quantitatively by using 
a proxy of the Charlson Comorbidity Index (CCI), which is 
a well- known validated index to measure comorbidity dis-
ease status (8). The CCI is a weighted score of 19 different 
comorbidities, selected according to their potential influ-
ence on mortality. The sum of the weights of each condition 
can range from 0 to 33, and the CCI score is an indicator 
of disease burden. The proxy we used (CCIp) consisted of 
a  minor modification of the original CCI, made by pooling all of 
the tumors (solid, leukemia, and lymphoma) into a single item, 
named Cancer. The remaining comorbidities were collected 
and rated as in the original CCI. Consequently, the sum of the 
 possible scores in our proxy ranged between 0 and 27.
Statistical analysis. Descriptive analyses were performed 
for the demographic and clinical variables. Afterward, bivariate 
analyses were conducted to investigate the associations between 
the independent variables and physical function. Numerical 
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 variables were assessed using Student’s t- test or the Mann- 
Whitney U test. Qualitative variables were assessed by chi- square, 
Yates’ correction, or Fisher’s exact tests in 2 × 2 tables. To study 
the association between single comorbidities or CCIp scores and 
physical function, 2 different multivariate linear models were per-
formed, with physical function as the dependent variable (BASFI 
and HAQ, respectively), adjusted for potentially confounding 
 factors.
The selection of the independent variables in the multivari-
ate models was based on those found to be statistically significant 
in the bivariate analyses and also on clinical judgement. Estimates 
for these associations are shown as beta coefficients, 95% con-
fidence intervals (95% CIs), and P values. All analyses were per-
formed using SPSS software, version 22.0. Statistical significance 
was assumed at a P value less than 0.05.
RESULTS
Clinical and demographic features of the patients 
and comorbidities. We analyzed 1,459 patients (738 AS and 
721 PsA) whose demographic and clinical features are summa-
rized in Supplementary Table 1, available on the Arthritis Care & 
Research web site at http://onlin elibr ary.wiley.com/doi/10.1002/
acr.23910/ abstract. Briefly, patients with AS had an earlier dis-
ease onset and were younger at the time of study inclusion than 
those with PsA. In addition, the AS cohort had a higher percent-
age of men than that of patients with PsA. A similar percentage 
of patients in both groups were receiving biologic therapies, 
but more patients with AS received nonsteroidal antiinflamma-
tory drugs (NSAIDs), whereas a higher number of patients with 
PsA used conventional synthetic disease- modifying antirheumatic 
drugs (DMARDs), combined therapies (synthetic plus biologic 
DMARDs), and glucocorticoids.
The comorbidities and CCIp percentages of the 2 groups are 
shown in Table 1. Regarding traditional CVD risk factors, patients 
with PsA had a higher body mass index (BMI) and hypercholes-
terolemia prevalence. In contrast, we found more current smokers 
among patients with AS. Apart from a higher prevalence of chronic 
obstructive pulmonary disease (COPD) among patients with AS 
and a nonsignificant increase of mild liver disease in patients 
with PsA, no other differences in the prevalence of the different 
comorbidities between the 2 groups were identified. Regarding 
the comorbidity burden, 21% of patients had >1 comorbidity 
(CCIp >1) in both groups; more specifically, patients with AS had 
a mean ± SD CCIp of 1.32 ± 0.73, whereas those with PsA had 
a CCIp of 1.30 ± 0.66.
Physical function and comorbidity. When we analyzed 
physical function distribution (using BASFI in the AS group and 
HAQ for patients with PsA) across different levels of comorbidity, 
we did not detect differences in patients with AS (median BASFI 
3.3 [interquartile range (IQR) 1.6–5.6] for patients with CCIp >1 
versus 3.0 [IQR 1.2–5.1] for those with CCIp = 1; P = 0.353). 
However, we observed that patients with PsA and more comor-
bidities had worse physical function (HAQ 0.75 [IQR 0.25–1.25] 
for CCIp >1) than patients with just 1 comorbidity (HAQ 0.25 [IQR 
0.0–0.75]; P < 0.001).
Independent variables associated with physical 
function. AS cohort. On bivariate analyses (Table 2), physical 
function was associated with age, female sex, disease dura-
tion, disease activity (BASDAI and ESR), and spinal radiograph-
ic damage. In addition, treatment with NSAIDs and glucocor-
ticoids was associated with physical function. In contrast, a 
higher education level was associated with less disability. We 
also identified an association between physical function and 
some individual comorbidities (obesity, hypertension, hiatal 
hernia, thyroid disease, or an increase in triglycerides) or the 
use of statins, on bivariate analyses. However, we did not iden-
tify an association between physical function and comorbidity 
burden (CCIp).






(n = 721) P
BMI, mean ± SD kg/m2 27.4 ± 4.4 28.2 ± 4.7 <0.001†
Hypertension 190 (25.7) 213 (29.5) 0.105
Hypercholesterolemia 199 (27) 257 (35.6) <0.001†
Obesity (BMI ≥30) 186 (25.2) 209 (29.1) 0.097
Current smokers 254 (34.4) 157 (21.8) <0.001†
Past smokers 240 (32.5) 227 (31.5) –
Never smokers 244 (33.1) 337 (46.7) –
Myocardial infarction 21 (2.9) 11 (1.5) 0.085
Congestive heart failure 4 (0.5) 7 (1.0) 0.344
Peripheral vascular 
disease
8 (1.1) 7 (1.0) 0.830
Dementia 1 (0.1) 0 (0.0) 0.323
Chronic obstructive 
pulmonary disease
20 (2.71) 9 (1.3) 0.045†
Ulcer disease 32 (4.3) 26 (3.6) 0.476
Diabetes mellitus 52 (7.1) 61 (8.5) 0.312
Cerebrovascular disease 3 (0.4) 0 (0.0) 0.087
Mild liver disease 20 (2.7) 33 (4.6) 0.057
Hemiplegia 0 (0.0) 0 (0.0) –
Moderate or severe 
renal disease
18 (2.4) 14 (1.9) 0.517
Diabetes mellitus with 
end-organ damage
3 (0.4) 5 (0.7) 0.458
Cancer‡ 17 (2.3) 16 (2.2) 0.914
Moderate or severe liver 
disease
4 (0.5) 2 (0.3) 0.430
Metastatic cancer 1 (0.1) 0 (0.0) 0.323
CCIp, median (IQR) 1 (1–1) 1 (1–1) 0.912
CCIp = 1 585 (79.3) 567 (78.6) –
CCIp >1 153 (20.7) 154 (21.4) 0.769
* Values are the number (%) unless indicated otherwise. AS = 
ankylosing spondylitis; PsA = psoriatic arthritis; BMI = body mass 
index; CCIp = Charlson Comorbidity Index proxy; IQR = interquartile 
range (25–75). 
† Statistically significant. 
‡ Solid tumors, leukemia, and lymphoma pooled. 
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In the multivariate model (Table 3), no association between 
physical function and comorbidity burden (CCIp) was found. 
Furthermore, age, disease activity (measured by BASDAI and 
ESR), and spinal radiographic damage were associated with 
higher disability. Also, treatment with biologic DMARDs was 
associated with physical function. At this point, no significant 
associations with sex or education level were identified in 
patients with AS.
PsA cohort. In patients with PsA, an independent associ-
ation between comorbidity burden and physical function was 
observed (Table 2). In this regard, the increase in CCIp was sig-
nificantly associated with higher disability (β = 0.11 [IQR 0.05–
0.17]) on the adjusted multivariate model (Table 3). In addition, 
we identified an association between physical function and age, 
female sex, disease duration, disease activity (DAS28- ESR), and 
use of NSAIDs, biologic DMARDs, and glucocorticoids, on bi-
variate analyses. Apart from age, all of the above- mentioned as-
sociations were confirmed in the multivariate model. Also, some 
comorbidities, such as obesity, hypertension, or the increase in 
triglycerides, were associated with physical function on bivariate 
analysis. Interestingly, a higher education level was associated 
with less disability in these patients.
DISCUSSION
The present multicenter national survey indicates that the 
presence of comorbidities may decrease the reported physi-
cal function of the patients with SpA. Comorbidity burden was 
independently associated with physical function in patients with 
PsA. Moreover, the study confirmed that comorbidity is common 
among patients with SpA. However, some differences between 
AS and PsA were observed. In this regard, some CVD risk fac-
tors, such as high BMI and hypercholesterolemia, were more 
prevalent in patients with PsA. In addition, obesity was associated 
with worse function on bivariate analysis in such patients. Obesity 
negatively influences not only CVD risk but also other disease out-
comes. In this regard, being obese and overweight reduces the 
chances to achieve minimal disease activity in patients with PsA 
receiving traditional or biologic DMARD therapy (9).
Smoking is known to be a harmful factor in patients with AS, 
leading to worse outcomes, including radiographic damage (10). 
In connection with that, in our survey we found that smoking habit 
and COPD were more common in patients with AS. Therefore, 
patients with AS should be encouraged to refrain from smoking 
as soon as a diagnosis of the disease is made.
Table 2. Comorbidity and physical function: variables associated with BASFI in patients with AS and with HAQ in 
patients with PsA, unadjusted estimates*
Variables
AS PsA
β 95% CI P β 95% CI P
Age at inclusion 0.04 (0.03, 0.06) <0.001† 0.01 (0.00, 0.01) <0.001†
Sex (ref. male) 0.74 (0.34, 1.14) <0.001† 0.36 (0.27, 0.44) <0.001†
Disease duration 0.02 (0.01, 0.04) <0.001† 0.01 (0.01, 0.02) <0.001†
Education level (ref. primary)
Basic 1.07 (0.08, 2.05) 0.03† 0.23 (0.04, 0.24) 0.02†
Secondary –0.16 (–0.59, –0.26) 0.45 –0.17 (–0.28, –0.06) <0.01†
University –1.01  (–1.46, –0.56) <0.001† –0.24  (–0.35, –0.13) <0.001†
CCIp 0.17 (–0.08, 0.41) 0.19 0.21 (0.14, 0.27) <0.001†
Obesity 0.77 (0.36, 1.19) <0.001† 0.19 (0.09, 0.29) <0.001†
Statins 0.66 (0.17, 1.15) 0.01† 0.08 (–0.02, 0.19) 0.13
Hypertension 0.74 (0.33, 1.15) <0.001† 0.20 (0.11, 0.30) <0.001†
Triglycerides‡ 0.40 (0.15, 0.65) <0.001† 0.11 (0.05, 0.17) <0.001†
GI bleeding 0.51 (–0.69, 1.71) 0.403 0.49 (–0.20, 1.19) 0.16
Hiatal hernia 1.39 (0.71, 2.07) <0.001† 0.17 (–0.02, 0.36) 0.07
Thyroid disease 1.60 (0.44, 2.76) 0.01† 0.18 (–0.01, 0.37) 0.06
NSAID 0.78 (0.41, 1.14) <0.001† 0.12 (0.03, 0.21) 0.01†
Biologic DMARD 0.21 (–0.14, 0.58) 0.240 0.12 (0.03, 0.21) 0.01†
GC 0.99 (0.33, 1.65) <0.001† 0.25 (0.13, 0.36) <0.001†
DAS28- ESR – NA – 0.24 (0.21, 0.27) <0.001†
BASDAI 0.82 (0.77, 0.88) <0.001† – NA –
ESR 0.03 (0.01, 0.04) <0.001† 0.01 (0.00, 0.01) <0.001†
Radiographic damage§ 0.82 (0.31, 1.34) <0.001† 0.03 (–0.07, 0.14) 0.499
* The dependent variable for patients with ankylosing spondylitis (AS) was the Bath Ankylosing Spondylitis Functional 
Index (BASFI; range 0–10) and for patients with psoriatic arthritis (PsA) was the Health Assessment Questionnaire 
(HAQ; range 0–3). 95% CI = 95% confidence interval; CCIp = Charlson Comorbidity Index proxy; GI = gastrointestinal; 
NSAID = nonsteroidal antiinflammatory drug; DMARD = disease- modifying antirheumatic drug; GC = glucocorticoids; 
DAS28- ESR = Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; NA = not applicable; BASDAI 
= Bath Ankylosing Spondylitis Disease Activity Index. 
† Statistically significant. 
‡ Triglycerides analyzed per 100 mg/dl increase. 
§ Defined as “spinal radiographic damage” in patients with AS and “presence of erosions” in patients with PsA. 
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Interestingly, we identified a relationship between comorbidity 
burden and physical function in patients with PsA. The most com-
monly reported factors affecting physical function in patients with 
PsA are disease activity and radiographic damage (4). However, 
we believe that comorbidity may also exert some negative influ-
ence on the physical function of patients with PsA, and our results 
support this view. In this case, the measurement of physical func-
tion would reflect not only the disease process but also other fac-
tors related to the patients’ general health. In this way, a recent 
study from the Assessment of Spondyloarthritis international Soci-
ety Comorbidities in Spondyloarthritis cohort identified a relation-
ship between comorbidity and functional status in patients with 
axial and peripheral SpA (11). The understanding of the different 
causes that impact the functional disability becomes more relevant 
now that remission- inducing therapies are available. However, the 
disability related to causes different from the disease itself may 
not be improved if they are not properly detected. Therefore, rec-
ognizing the comorbid conditions that overshadow the outcome 
of patients with SpA is important. In fact, recommendations for 
their identification and management have been recently published 
(12). However, to ascertain the impact of the comorbidity control 
on long- term outcomes such as function, longitudinal studies are 
needed.
A recent study showed an association between comorbid-
ity burden and physical function in patients with SpA (11), but 
we could not confirm this association in our patients with AS. 
 Methodologic differences, such as different populations and the 
use of different indexes to measure comorbidity burden, may 
explain such a discrepancy. Moreover, since comorbidity has 
been reported to be a major contributor to functional limitation 
in late AS (13), this association may be more evident in patients 
with longstanding AS, due to the increase of comorbidities with 
aging.
Our study also revealed an association between female 
sex and worse function in patients with PsA. This finding is in 
agreement with previous reports that showed an association of 
female sex with worse function and quality of life (14). In patients 
with AS, we identified an association between female sex and 
worse function, but the association was not confirmed on the 
adjusted multivariate model. The impact of sex on function is 
still unclear in patients with AS, with some cross- sectional stud-
ies reporting worse function among women with AS, whereas 
a prospective study did not identify sex differences  in dis-
ease activity or physical function over time in AS (15). In our 
study, although the bivariate analysis showed worse function in 
women with AS, worse function was not confirmed by the mul-
tivariate model.
The association between higher education level and lower 
reported disability identified in our patients with PsA has already 
been reported in patients with SpA (11). The fact that the educa-
tion level can influence the way in which the patients handle, or 
report, their disease process cannot be dismissed.
Finally, other well- recognized factors with an impact on 
physical function, such as age, disease activity, and radiographic 
damage in patients with AS (3), as well as disease duration and 
disease activity in patients with PsA (4), were also associated with 
Table 3. Comorbidity and physical function: variables associated with BASFI in patients with AS and with 
HAQ in patients with PsA, adjusted multivariate model*
Variables
AS PsA
β 95% CI P β 95% CI P
Age at inclusion 0.03 (0.02, 0.05) <0.001† 0.00 (–0.00, 0.00) 0.906
Sex (ref. male) –0.11 (–0.38, 0.16) 0.430 0.14 (0.06, 0.22) <0.001†
Disease duration 0.01 (–0.00, 0.02) 0.095 0.01 (0.00, 0.01) 0.015†
Education level (ref. primary)
Basic 0.21 (–0.45, 0.86) 0.532 0.14 (–0.03, 0.31) 0.096
Secondary 0.01 (–0.26, –0.29) 0.925 –0.08 (–0.17, –0.01) 0.093
University –0.22 (–0.52, 0.08) 0.154 –0.14 (–0.24, –0.04) 0.004†
CCIp 0.03 (–0.13, 0.20) 0.701 0.11 (0.05, 0.17) <0.001†
NSAID 0.11 (–0.14, 0.37) 0.390 0.09 (0.02, 0.17) 0.017†
Biologic DMARD 0.51 (0.27, 0.76) <0.001† 0.15 (0.07, 0.23) <0.001†
GC 0.03 (–0.40, 0.46) 0.899 0.11 (0.01, 0.21) 0.026†
DAS28- ESR – NA – 0.19 (0.16, 0.22) <0.001†
BASDAI 0.81 (0.75, 0.86) <0.001† – NA –
ESR 0.01 (0.00, 0.02) 0.013† – NI –
Radiographic damage‡ 0.61 (0.28, 0.95) <0.001† – NI –
* The dependent variable for patients with ankylosing spondylitis (AS) was the Bath Ankylosing Spondylitis 
Functional Index (BASFI; range 0–10) and for patients with psoriatic arthritis (PsA) was the Health Assessment 
Questionnaire (HAQ; range 0–3). 95% CI = 95% confidence interval; CCIp = Charlson Comorbidity Index 
proxy; NSAID = nonsteroidal antiinflammatory drug; DMARD = disease- modifying antirheumatic drug; GC 
= glucocorticoids; DAS28- ESR = Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; 
NA = not applicable; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; NI = not included in the 
multivariate model. 
† Statistically significant. 
‡ Defined as “spinal radiographic damage” in patients with AS and “presence of erosions” in patients with PsA. 
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worse function in our study. Likewise, the association between the 
use of biologics in AS, and the use of NSAIDs, glucocorticoids, 
and biologics in PsA, with worse physical function, would proba-
bly indicate more severe disease.
Among the strengths of our study, we highlight the large 
nationwide sample of patients from daily clinical practice that, 
unlike patients included in clinical trials, had different levels of 
comorbidity and disability. Thus, the results are representative of 
Spanish patients with SpA (AS and PsA) attending rheumatology 
outpatient clinics.
Nevertheless, this study has several limitations. First, it had 
a cross- sectional nature, which precludes causal inferences. 
Second, we used a proxy of the CCI. However, we judged this 
proxy as a useful estimate of the comorbidity burden in our cohort, 
because the information collected was not complete to apply the 
original CCI. Since there is no standard comorbidity index cur-
rently used in rheumatology research, variations of the CCI are 
used because they have been extensively validated throughout 
different medical and research contexts. However, the CCI was 
primarily developed to predict mortality and not functional dis-
ability. Furthermore, our proxy was not able to overcome the fact 
that the CCI does not include osteoporosis or depression, highly 
prevalent comorbidities in patients with AS and PsA that may also 
be relevant to physical disability. Third, although definitions for 
radiographic damage in both diseases were used in the CARMA 
study protocol, quantification of radiographic damage by using 
validated scores was not performed. This fact may explain the 
lack of association between function and radiographic damage 
in patients with PsA. Nevertheless, since several studies have 
shown a close relationship between radiographic progression and 
disease duration, the multivariate models performed in our study 
were also adjusted for the effects of disease duration.
In conclusion, as shown in our large series of patients with 
SpA who were followed up at outpatient rheumatology units, 
the presence of comorbidities may decrease the reported phys-
ical function of patients with SpA. In this setting, a high preva-
lence of comorbidities has been shown. More importantly, as the 
comorbidity burden increases, the reported physical function of 
the patients with PsA decreases. The detection and control of the 
comorbidities may yield an integral management of the disease.
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APPENDIX A: CARDIOVASCULAR IN RHEUMATOLOGY 
PROJECT COLLABORATIVE GROUP
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na); Martina Steiner, Santiago Muñoz (Hospital Infanta Sofía, Madrid); 
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pital Universitario de Guadalajara); Raimon Sanmartí, Horacio Berman, 
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Antonio Fernández Nebro, Sara Manrique Arija, María Angeles Belmonte 
López, Inmaculada Ureña, María V. Irigoyen, Virginia Coret Cagigal 
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Zaragoza);  Soledad Ojeda, Juan Carlos Quevedo, Félix Francisco, 
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Provincial de Rehabilitación, Madrid); Francisco J. González Polo (Hospi-
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María Teresa Navío (Hospital Infanta Leonor, Madrid); Encarnación 
Pagán, Pablo Mesa del Castillo (Hospital Los Arcos, Murcia); Esperanza 
Naredo, Ana Cruz (Hospital Severo Ochoa, Madrid); Isabel Mateo, Julio 
Sánchez, María Galindo, Javier García González (Hospital Universitar-
io 12 de Octubre, Madrid); Eduardo Collantes, Desiree Ruiz, Pilar Font 
(Hospital Universitario Reina Sofía, Córdoba); Gema Bonilla (Hospital 
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